Literature DB >> 27007859

Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling.

Rong Fu1, Peter B Gilbert2,3.   

Abstract

A common objective of cohort studies and clinical trials is to assess time-varying longitudinal continuous biomarkers as correlates of the instantaneous hazard of a study endpoint. We consider the setting where the biomarkers are measured in a designed sub-sample (i.e., case-cohort or two-phase sampling design), as is normative for prevention trials. We address this problem via joint models, with underlying biomarker trajectories characterized by a random effects model and their relationship with instantaneous risk characterized by a Cox model. For estimation and inference we extend the conditional score method of Tsiatis and Davidian (Biometrika 88(2):447-458, 2001) to accommodate the two-phase biomarker sampling design using augmented inverse probability weighting with nonparametric kernel regression. We present theoretical properties of the proposed estimators and finite-sample properties derived through simulations, and illustrate the methods with application to the AIDS Clinical Trials Group 175 antiretroviral therapy trial. We discuss how the methods are useful for evaluating a Prentice surrogate endpoint, mediation, and for generating hypotheses about biological mechanisms of treatment efficacy.

Entities:  

Keywords:  Case-cohort; Measurement error; Prentice surrogate endpoint evaluation; Proportional hazards model; Random effects model

Mesh:

Substances:

Year:  2016        PMID: 27007859      PMCID: PMC5035179          DOI: 10.1007/s10985-016-9364-1

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  13 in total

1.  An estimator for the proportional hazards model with multiple longitudinal covariates measured with error.

Authors:  Xiao Song; Marie Davidian; Anastasios A Tsiatis
Journal:  Biostatistics       Date:  2002-12       Impact factor: 5.899

2.  Evaluating surrogate markers of clinical outcome when measured with error.

Authors:  U G Dafni; A A Tsiatis
Journal:  Biometrics       Date:  1998-12       Impact factor: 2.571

3.  Estimating the proportion of treatment effect explained by a surrogate marker.

Authors:  D Y Lin; T R Fleming; V De Gruttola
Journal:  Stat Med       Date:  1997-07-15       Impact factor: 2.373

4.  A joint model for survival and longitudinal data measured with error.

Authors:  M S Wulfsohn; A A Tsiatis
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

5.  A new proportion measure of the treatment effect captured by candidate surrogate endpoints.

Authors:  Fumiaki Kobayashi; Manabu Kuroki
Journal:  Stat Med       Date:  2014-04-29       Impact factor: 2.373

6.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

7.  Modelling progression of CD4-lymphocyte count and its relationship to survival time.

Authors:  V De Gruttola; X M Tu
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

8.  osDesign: An R Package for the Analysis, Evaluation, and Design of Two-Phase and Case-Control Studies.

Authors:  Sebastien Haneuse; Takumi Saegusa; Thomas Lumley
Journal:  J Stat Softw       Date:  2011-08       Impact factor: 6.440

9.  Improving efficiency and robustness of the doubly robust estimator for a population mean with incomplete data.

Authors:  Weihua Cao; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrika       Date:  2009-08-07       Impact factor: 2.445

10.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

View more
  2 in total

1.  A joint model for mixed and truncated longitudinal data and survival data, with application to HIV vaccine studies.

Authors:  Tingting Yu; Lang Wu; Peter B Gilbert
Journal:  Biostatistics       Date:  2018-07-01       Impact factor: 5.899

2.  Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.

Authors:  Ying Huang; Brian D Williamson; Zoe Moodie; Lindsay N Carpp; Laurent Chambonneau; Carlos A DiazGranados; Peter B Gilbert
Journal:  J Infect Dis       Date:  2022-01-18       Impact factor: 7.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.